AN2 Therapeutics has signed an exclusive licence agreement with the University of Georgia Research Foundation to advance the development of a new boron-containing small molecule to treat Chagas disease.
The boron-based molecules were initially discovered by a team of researchers from Pfizer’s wholly-owned subsidiary Anacor Pharmaceuticals and the University of Georgia, using non-dilutive grant funding from Wellcome.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The key compound in this series, AN2-502998, was discovered in partnership with Professor Rick Tarleton from the University of Georgia.
Wellcome has supported preclinical activities, carried out in collaboration with Tarleton.
AN2 Therapeutics co-founder, president and CEO Eric Easom stated: “AN2-502998 is the only compound to date that demonstrates complete cures of infection in non-human primates with long-term, naturally acquired chronic infections of diverse T cruzi genetic types.
“Professor Tarleton and scientists from AN2 have advanced this research, and with IND-enabling preclinical studies for AN2-502998 well underway and this licence in hand, we are excited to further develop AN2-502998 as a potential treatment for Chagas disease.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe World Health Organisation (WHO) declared Chagas disease to be a neglected tropical disease.
It is caused by the Trypanosoma cruzi (T cruzi) parasite that spreads through a subspecies of blood-feeding insects commonly known as “kissing bugs”.
The WHO estimates that seven million people worldwide are infected with the parasite.
